Overview
Maravai Q3 revenue falls 39.7% yr/yr, missing analyst expectations
Adjusted EBITDA for Q3 misses analyst estimates, reflecting operational challenges
Biologics Safety Testing revenue grows 7.2% yr/yr, driven by strong product lines
Outlook
Maravai expects full-year 2025 revenue to be approximately $185 mln
Company anticipates TriLink to achieve double-digit sequential revenue growth in Q4 2025
Maravai aims for attractive financial results in Q4 2025 and 2026
Result Drivers
NUCLEIC ACID PRODUCTION - Revenue decreased 52.9% due to lack of high-volume CleanCap orders and non-recurring large GMP orders
BIOLOGICS SAFETY TESTING - Revenue increased 7.2% due to strength in nearly all product lines
RESTRUCTURING AND COST REDUCTION - Organizational restructuring and cost reduction initiatives are on track, expected to improve future financial results
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $41.60 mln | $49.003 mln (11 Analysts) |
Q3 Net Income | -$45.10 mln | ||
Q3 Adjusted EBITDA | Miss | -$10.80 mln | -$7.41 mln (10 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Maravai LifeSciences Holdings Inc is $4.50, about 36.2% above its November 5 closing price of $2.87
Press Release: ID:nBwFVVXFa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)